Arthneeti
All Q2 FY27 results →
FT

Fabtech Technologies Ltd

Q2 FY27Healthcare Services

Fabtech Technologies Q2 Results 2026 (FY27): Revenue ₹900 Cr, EBITDA margin 16.0%

Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.

Price₹122
Market cap₹544 Cr
P/E11.2
Updated30 Oct 2026
Read5 min read

Fabtech Technologies Ltd Q2 FY27 key numbers

Revenue
Q2FY27 Revenue from Operations: ₹920.9 Mn.

As stated in Fabtech Technologies Ltd's Q2 FY27 investor presentation · published 29 Oct 2026. Reported figures, not investment advice.

Based on Fabtech Technologies Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

The short version

Q2FY27 Revenue from Operations: ₹920.9 Mn - Q2FY26 Revenue from Operations: ₹1,214.8 Mn - Year-on-Year Change: Decrease of 24.2% (₹920.9 Mn vs ₹1,214.8 Mn) - H1FY27 Revenue from Operations: ₹1,670.7 Mn - H1FY26 Revenue from Operations: ₹1,894.9 Mn - Year-on-Year Change for H1: Decrease of 11.9% Outlook: - Revenue recovery expected in H2 FY27 as project milestones are achieved (Page 6). Q2 FY27 EBITDA: INR 155.7 Mn, up 110.0% QoQ; EBITDA margin 16.0% (compared to 26.8% in Q2 FY26). - Reported PAT Q2 FY27: INR 150.2 Mn, compared to INR 281.1 Mn in Q2 FY26 (a decrease in PAT margin from 23.1% to 16.3%). - Adjusted PAT Q2 FY27: INR 84.3 Mn; Adjusted PAT margin 9.2% vs 23.1% in Q2 FY26. - Year-on-Year (YoY) change: Revenue from operations for Q2 FY27 was INR 920.9 Mn vs.

From Fabtech Technologies Ltd's Q2 FY27 earnings-call transcript · updated 30 Oct 2026.

Revenue & Sales Performance

- **Q2FY27 Revenue from Operations:** ₹920.9 Mn - **Q2FY26 Revenue from Operations:** ₹1,214.8 Mn - **Year-on-Year Change:** Decrease of 24.2% (₹920.9 Mn vs ₹1,214.8 Mn) - **H1FY27 Revenue from Operations:** ₹1,670.7 Mn - **H1FY26 Revenue from Operations:** ₹1,894.9 Mn - **Year-on-Year Change for H1:** Decrease of 11.9% **Outlook:** - Revenue recovery expected in H2 FY27 as project milestones are achieved (Page 6). - Management confident of achieving adjusted PAT margin of 8–9% in FY27, implying improved profitability with revenue normalization.

2 more points from Fabtech Technologies Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Fabtech Technologies Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • The presentation mentions expansion in pharmaceutical and healthcare manufacturing capacity across emerging markets as a structural driver (Page 13).
  • Fabtech’s global presence includes local teams and engineering bases in India, UAE, Saudi Arabia, Jordan, Egypt, Algeria, and Nigeria supporting regional growth (Page 22).
  • Strategic priority includes advancing capabilities in cell and gene therapy facilities and other high-tech projects, plus data-center infrastructure (Page 9).
  • Exploration of an operational opportunity in Europe is targeted for Q4 FY27 or Q1 FY28, subject to due diligence and approvals (Page 9).

2 more points from Fabtech Technologies Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
1Health X Platform
Rev 1Mar 1
2Chandan Healthca
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 2
5
Rev 2Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Fabtech Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Closing unexecuted order book stood at Rs 900 crore at the end of FY26.
  • Order inflow during FY26 was Rs 500+ crore.
  • The unexecuted orders are executable over 12–18 months.
  • Gross receivables as of 31st March 2026 were Rs 204 crore, with advances from customers at Rs 47 crore.
  • The order intake for FY26 is ~94% driven by GCC, MENA, and ECO regions.

2 more points from Fabtech Technologies Ltd's call on order book

Create a free account to keep reading this call

Fabtech Technologies Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹92 Cr, net profit ₹15 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Fabtech Technologies Ltd's management said in earlier quarters

Others in Healthcare Services this season

  • Narayana Hrudayalaya Ltd (Q2 FY27)

    Consolidated operating revenue for Q2 FY27: ₹28,440 Mn, up 73.0% YoY (Page 15, 16). Key investor presentation takeaways from Narayana Hrudayalaya Ltd's Q2 FY27

  • Artemis Medicare Services Ltd (Q2 FY27)

    Q2 FY27 consolidated revenue from operations: INR 31,104 Lacs, up 13.2% YoY (Page 39, 40, 20). Key investor presentation takeaways from Artemis Medicare Service

  • Max Healthcare Institute Ltd (Q2 FY27)

    Q2 FY27 Gross Revenue: ₹3,219 Cr, up 20% YoY (Page 4, 17) . Key investor presentation takeaways from Max Healthcare Institute Ltd's Q2 FY27 investor presentatio

  • Indegene Ltd (Q2 FY27)

    Revenue from operations for Q2 FY27: INR 11,223 million, up 39.5% YoY (Page 23, 15, 4) . Key investor presentation takeaways from Indegene Ltd's Q2 FY27 investo

Compare:vs Apollo Hospitals Enterprise Ltdvs Manipal Health Enterprises Ltdvs Max Healthcare Institute Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Fabtech Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Fabtech Technologies Ltd Q2 FY27 results?

Q2FY27 Revenue from Operations: ₹920.9 Mn - Q2FY26 Revenue from Operations: ₹1,214.8 Mn - Year-on-Year Change: Decrease of 24.2% (₹920.9 Mn vs ₹1,214.8 Mn) - H1FY27 Revenue from Operations: ₹1,670.7 Mn - H1FY26 Revenue from Operations: ₹1,894.9 Mn - Year-on-Year Change for H1: Decrease of 11.9% Outlook: - Revenue recovery expected in H2 FY27 as project milestones are achieved (Page 6). Q2 FY27 EBITDA: INR 155.7 Mn, up 110.0% QoQ; EBITDA margin 16.0% (compared to 26.8% in Q2 FY26). - Reported PAT Q2 FY27: INR 150.2 Mn, compared to INR 281.1 Mn in Q2 FY26 (a decrease in PAT margin from 23.1% to 16.3%). - Adjusted PAT Q2 FY27: INR 84.3 Mn; Adjusted PAT margin 9.2% vs 23.1% in Q2 FY26. - Year-on-Year (YoY) change: Revenue from operations for Q2 FY27 was INR 920.9 Mn vs.

What is Fabtech Technologies Ltd share price analysis?

Fabtech Technologies Ltd currently shows a neutral. The stock trades at a P/E of 11.2 with a market cap of ₹544 Cr. Investors should review the full earnings analysis for detailed insights.

Is Fabtech Technologies Ltd planning capital expenditure?

The presentation mentions expansion in pharmaceutical and healthcare manufacturing capacity across emerging markets as a structural driver (Page 13).

Keep Fabtech Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.